Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Self-management of Inpatient Insulin
NCT02144441Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- Jun 2014
- Primary completion
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of insulin glargine and insulin aspart in diabetes mellitus (DM), sponsored by University of Pennsylvania. Primary endpoints: Trial feasibility metric: number of screened patients at 3 months, Trial feasibility metric: number of eligible patients at 3 months and 7 more. Planned start Jun 2014; status: withdrawn.
02
Drugs
insulin glargineinsulin aspart
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02144441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02144441.